Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05361382 · ClinicalTrials.gov registry record · Phase 1
Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease
A Phase 1 study of Alzheimer Disease, sponsored by Tharick Pascoal.
- Active
- Registry status
- Phase 1
- Development phase
- 822
- Enrollment target
- 9
- Study locations
NCT05361382 is a Phase 1 study of Alzheimer Disease that is active but no longer recruiting, run by Tharick Pascoal. The registered enrollment target is 822 participants, below the 2,748-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (70% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT05361382, a Phase 1 study of Alzheimer Disease, is active but no longer recruiting, sponsored by Tharick Pascoal.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 822 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to compare/harmonize cross-sectional and longitudinal tau tangle measurements obtained with the tau PET radiopharmaceuticals Flortaucipir and MK-6240 to elucidate the advantages and caveats of their use in clinical trials/practice and provide parameters to integrate their estimates.
Conditions Studied
Interventions
- DRUG 18F-Flortaucipir radiopharmaceutical
- DRUG 18F-MK-6240 radiopharmaceutical
- DRUG Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)
Study Locations (9)
California
- Lawrence Berkeley National Laboratory - Berkeley
- University of California San Francisco - San Francisco
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University in St. Louis - St Louis
Pennsylvania
- University of Pittsburgh - Pittsburgh
Rhode Island
- Brown University - Providence
Texas
- Houston Methodist Neurological Institute - Houston
Quebec
- McGill University - Montreal
Spain
- Sant Pau Biomedical Research Institute - Barcelona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 822 participants |
| Start Date | 2022-03-02 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05361382
The ClinicalTrials.gov registry entry for NCT05361382 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 822 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,748-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (70% lower). The listed sponsor is Tharick Pascoal, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 3 interventions - of which 18F-Flortaucipir radiopharmaceutical is the first listed.
NCT05361382 reports 9 study locations spanning 8 distinct geographic areas - top geographies include California, Minnesota, Missouri.
Frequently Asked Questions
What is clinical trial NCT05361382 about?
NCT05361382 is a clinical study titled "Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease". The purpose of this study is to compare/harmonize cross-sectional and longitudinal tau tangle measurements obtained with the tau PET radiopharmaceuticals Flortaucipir and MK-6240 to elucidate the advantages and caveats of their use in clinical trials/practice and provide parameters to integrate thei...
What is the current status of trial NCT05361382?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 822 participants. The study started on 2022-03-02. Estimated completion is 2027-05-31.
What conditions does trial NCT05361382 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT05361382?
The interventions under investigation include: 18F-Flortaucipir radiopharmaceutical (DRUG), 18F-MK-6240 radiopharmaceutical (DRUG), Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol) (DRUG).
Who is sponsoring clinical trial NCT05361382?
This trial is sponsored by Tharick Pascoal, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05361382 being conducted?
This trial has 9 study locations across California, Minnesota, Missouri, Pennsylvania, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.